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procedure. 
RESULTS
308 patients were included and a single polypectomy 
was performed in 205. Only 36 (11.7%) were on prior 
anticoagulant therapy. Mean polyp size was 15 ± 8.9 
mm (5-60) and in 294 cases (95.4%) were located in 
the stomach. Hemorrhage prophylaxis was performed 
in 219 (71.1%) patients. Nine patients presented AEs 
(2.9%), and 6 of them were bleeding (n  = 6, 1.9%) (in 
5 out of 6 AE, different types of endoscopic treatment 
were performed). Other 24 hemorrhagic episodes could 
be managed without any change in the outcome of 
the endoscopy and, consequently, were considered 
incidents. We did not find any independent risk factor 
of bleeding.
CONCLUSION
Gastroduodenal polypectomy using prophylactic 
measures has a rate of AEs small enough to consider 
this procedure a safe and effective method for polyp 
resection independently of the polyp size and location.
Key words: Polypectomy; Bleeding; Adverse events; 
Protruded polyps; Gastroduodenal; Foregut
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The safety of polypectomy in the upper 
gastroduodenal tract is controversial because the 
reported rate in retrospective studies is higher than 
in colonic polypectomy but results come mainly from 
retrospective studies and they do not use the same 
standardized nomenclature and definitions for adverse 
events. To our knowledge, this is the first study using 
the ASGE lexicon for reporting adverse events of 
gastro-duodenal polypectomy and shows an acceptable 
low rate, confirming the safety of this procedure.
Córdova H, Argüello L, Loras C, Naranjo Rodríguez A, Riu Pons 
F, Gornals JB, Nicolás-Pérez D, Andújar Murcia X, Hernández 
L, Santolaria S, Leal C, Pons C, Pérez-Cuadrado-Robles E, 
García-Bosch O, Papo Berger M, Ulla Rocha JL, Sánchez-
Montes C, Fernández-Esparrach G. Rate of adverse events of 
gastroduodenal snare polypectomy for non-flat polyp is low: A 
prospective and multicenter study. World J Gastroenterol 2017; 
23(47): 8405-8414  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v23/i47/8405.htm  DOI: http://dx.doi.
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INTRODUCTION
Gastric polyps are found in around 3%-6% of patients 
undergoing upper endoscopy[1,2]. According to these 
sources, the most common gastric polyps are the 
hyperplastic and fundic gland types (70%-90%) 
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Abstract
AIM
To evaluate the rate of adverse events (AEs) during 
consecutive gastric and duodenal polypectomies in 
several Spanish centers. 
METHODS
Polypectomies of protruded gastric or duodenal polyps 
≥ 5 mm using hot snare were prospectively included. 
Prophylactic measures of hemorrhage were allowed 
in predefined cases. AEs were defined and graded 
according to the lexicon recommended by the American 
Society for Gastrointestinal Endoscopy. Patients were 
followed for 48 h, one week and 1 mo after the 
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followed by adenomas, with a variable prevalence 
among countries depending on the use of proton pump 
inhibitor drugs (PPI) or the prevalence of Helicobacter 
pylori (H. pylori) infection. In western countries, where 
H. pylori infection is low and PPI use is very common, 
fundic gland polyps are seen more frequently[2,3]. 
However, two retrospective Spanish series showed that 
in Spain the most frequent were hyperplastic polyps 
(50.9%), followed by fundic gland polyps (7.4%), 
adenomas (3%), and adenocarcinomas (1.9%)[4,5].
Sporadic duodenal polyps are uncommon with a 
prevalence of 0.3% to 4.6%[6,7]. Whereas multiple, 
small polyps in the duodenal bulb are benign a 
substantial number of them located in the descending 
duodenum are adenomas[7]. Duodenal adenomas can 
occur sporadically or more commonly in patients with 
Familial Adenomatous Polyposis, occurring in 50% 
to 100%[8]. Most of gastric and duodenal polyps are 
asymptomatic and are incidentally found at endoscopy 
performed for unrelated reasons.
Gastric and duodenal polyps have a risk of mali-
gnant transformation that depends on histologic 
type. The risk of gastric polyps undergoing malignant 
transformation is near 2% for hyperplasic polyps, 5% 
for tubular adenoma, and up to 30% for tubulovillous 
adenoma[9-11]. However, polyp histology cannot be 
reliably distinguished by endoscopic appearance[12,13] 
and biopsy is not always representative of the entire 
polyp[14]. Therefore, polypectomy is warranted if 
feasible and clinically appropriate; this is supported by 
current guidelines[15,16].
Endoscopic polypectomy has become standard in 
the management of most polyps in the gastrointestinal 
tract. Gastric and duodenal polyps can be safely 
removed with snare depending on size, location and 
presence of a stalk. However, bleeding is the most 
common adverse event (AE) of snare polypectomy, 
with an incidence of 6% to 7.2% in gastric polyps 
and up to 13.9% in duodenal polyps[17,18]. Although 
these figures are higher than those reported in 
colonic polypectomies (0.3%-6%)[19,20], the available 
evidence is limited by the fact that it is often based 
on retrospective studies performed at a single 
center or with a small number of patients and the 
nomenclature and definitions used for AEs are 
different. The need for standardized nomenclature and 
agreement on definitions for AEs was addressed by 
the American Society for Gastrointestinal Endoscopy 
(ASGE) in a workshop celebrated in 2008 and 
whose recommendations were published in 2010[21]. 
Moreover, there are few studies that specifically 
evaluate risk factors and the efficacy of different 
hemostatic techniques in the prevention and control of 
post-polypectomy bleeding.
The aim of this study was to estimate the incidence 
and risk factors of several types of AEs associated 
with gastroduodenal polypectomy in several Spanish 
hospitals using a standardized lexicon specific for 
endoscopic procedures.
MATERIALS AND METHODS
Patients
This is a prospective multicenter study performed at 15 
Spanish hospitals. Patients with gastric and duodenal 
polyps that underwent endoscopic polypectomy 
were eligible for inclusion in the study. All patients 
included in the study had been previously diagnosed of 
gastric polyps and subsequently underwent a second 
endoscopy to perform the polypectomy. Therefore, 
when the physicians were aware that they had to 
perform the polypectomy, they previously asked the 
patient for consent to participate in the study. Inclusion 
criteria were: (1) protruded gastric or duodenal polyps 
≥ 5 mm; and (2) polypectomy performed using an 
electrocautery snare. The exclusion criteria were: (1) 
age under 18 years; (2) prothrombin time < 50% 
or INR > 1.5 and platelet count < 50000 (blood test 
were only mandatory in patients with anticoagulation 
therapy or with conditions associated with coagulation 
disturbances); (3) aspirin intake during the previous 3 d; 
(4) clopidogrel intake during the previous 7 d; and (5) 
conditions associated with coagulation disturbances. 
The study protocol was approved by the Ethics 
Committee of each hospital and informed consent was 
obtained from all patients.
Three days before the procedure, oral anti-
coagulants were replaced by subcutaneous low-
molecular weight heparin. The patients were guided to 
reintroduce them 24-h after the procedure (the dose 
depended on the value of the previous INR value). 
Aspirin and clopidogrel were also reintroduced at usual 
doses. 
Snare polypectomy was performed according to the 
conventional method encircling the polyp with a poly-
pectomy snare and applying electrocautery current[22]. 
Patients were placed in the left lateral decubitus position 
and sedation was administered according to the 
endoscopist or anaesthesiologist’s preference.
Variables were recorded in database templates. 
The database included demographic characteristics, 
medical and drug history, indication of upper endo-
scopy, endoscopists’ expertise (staff or fellow), 
morphological features and localization of polyps, 
technical information about the polypectomy pro-
cedure (bloc/peacemeal resection, cautery setting, 
hemorrhage prophylaxis technique), type of sedation, 
unexpected events and measures for correcting them, 
and patient outcome. Polyp size was determined 
endoscopically using an open biopsy forceps (7 mm in 
length, Boston Scientific Large Capacity with Needle 
Biopsy Forceps 2.8 mm). In cases with multiple polyps, 
the biggest one’s characteristics were recorded. 
Definition of AEs
AEs were defined, following the lexicon of ASGE 
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After the procedure, bleeding was defined as a drop 
in Hb > 2 gr/dL or clinical evidence of bleeding (melena 
or hematemesis).
Bleeding prophylaxis
Prophylaxis of hemorrhage was allowed in the following 
situations:
Pedunculated polyps (Paris type 0-Ip): (1) Stalk ≥ 
5 mm and/or head ≥ 20 mm: adrenaline injection or 
endoloop before or immediately after polypectomy; 
and (2) Visible vessel after polypectomy: adrenaline 
injection, endoloop or hemostatic clip.
Sessile polyps (Paris type 0-Is): oozing bleeding 
with spontaneous hemostasis in less than 30 s and 
polyp size > 20 mm: adrenaline injection, argon plasma 
coagulation (APC) or hemostatic clip[23]. The technique 
was selected based on physician’s preference.
Statistical analysis
Sample size calculation was performed assuming 10% 
of AE from the previous data published[24,25]. With these 
numbers, we calculated that a total of 300 patients 
were required to achieve statistical significance (α 
error = 0.05, β error = 0.1). 
Continuous variables were expressed as mean ± 
SD. In cases with a multiple polypectomy, data provided 
correspond to the biggest one. Analysis was performed 
per patient and not per polyp. 95% confidence interval 
(CI) of AEs incidence was calculated by using standard 
formula. Comparisons were done using Fisher’s test for 
categorical variables and t test for continuous variables. 
The chi-squared test and the Mann-Whitney U test, 
or Student’s t-test were applied where appropriate for 
statistical analysis. In addition, a multivariate logistic 
regression analysis was carried out to assess the 
existence of predictive factors of AEs and the odds ratio 
(OR) was calculated to indicate the associated risk. P < 
0.05 was considered statistically significant. All analyses 
were performed with SPSS for Windows, version 23.0 
(SPSS Inc, Chicago, IL; United States).
RESULTS
From September 2012 to March 2015, a total of 
326 patients with gastroduodenal polyps agreed to 
participate in the study. 18 patients were excluded 
because they did not meet inclusion criteria (polyp < 
5 mm, n = 1; platelets < 50.000, n = 1; cold snare 
polypectomy, n = 9; Paris classification IIb or IIc polyp, 
n = 7). Then, 308 patients were finally included (Figure 
1). Most of them were ASA I-II (n = 231, 75%) and 
only 36 (11.7%) were on anticoagulants. The most 
frequent indication was iron-deficiency anemia (n 
= 103, 33.4%). Characteristics of the patients are 
described in Table 1.
In 205 cases a single polypectomy was performed 
whereas in the other 103 it was multiple (mean 1.7 ± 
1.3, range 1-7). Polyp mean size was 15 ± 8.9 mm 
Workshop[21], as an event that prevents completion of 
the polypectomy (planned procedure) and/or results in 
admission to hospital, prolongation of existing hospital 
stay, another procedure (needing sedation/anesthesia), 
or subsequent medical consultation. Unplanned events 
that did not interfere with completion of the planned 
procedure or changed the plan of care were classified 
as incidents. 
Severity of AEs was graded as mild, moderate, 
severe and fatal according to ASGE classification. 
AEs were defined as mild or moderate if patients 
required less than 4 nights or between 4 to 10 nights 
of hospitalization respectively. They were classified as 
severe if unplanned or prolonged hospitalization was 
required for more than 10 nights or requiring intensive 
care unit admission or surgery. Finally they were 
graded as fatal if death occurred in relationship of the 
procedure.
Based on timing, AEs were defined as “intra-
procedure” if they occurred during the exploration or in 
the recovery area, “early” if they occurred within 14 d 
and "late" from day 15th onward after polypectomy. 
Assessment of AEs
AEs were assessed and recorded by a physician 
during and after the procedure while the patient was 
recovering from sedation or anesthesia and up to 24 h 
later in those admitted for observation. At 48 h, one 
week and day 30 after the procedure, a telephone call 
was made in order to ask the patient whether they 
had experienced any symptoms or required medical 
assistance. A standard questioner was used for the 
evaluation of late complications. Responses were 
recorded and entered into a database.
The completeness of data collection was monitored 
every 2 wk and missing data were proactively collected 
by contacting the patients and/or referring physicians, 
as far as this was possible.
Definition of hemorrhage 
Bleeding was recorded as a potential AE when it 
required any form of intervention, either immediately 
after polypectomy during the index endoscopy, or in a 
repeat endoscopy, regardless of obtaining hemostasis, 
hospital admission, blood transfusion, or surgery. 
Depending on its activity, bleeding was classified as 
spurting or oozing; depending on its timing, it was 
classified as immediate-onset bleeding (evident during 
the examination) or late-onset bleeding (evident after 
the examination). 
Immediate postpolypectomy bleeding was 
graded from G1 to G4 in severity based on objective 
endoscopic findings based on the time and continuity 
of bleeding as previously described (G1: Spontaneous 
hemostasis within 60 s, G2: Continuous but decreased 
oozing over 60 seconds, G3: Continuous oozing over 
60 s that needs endoscopic treatment and G4: Active 
spurting)[23].
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(5-60) and 179 of them (58.1%) were > 10 mm. The 
majority of them were located in the stomach (n = 
294, 95.4%). The most frequent histological type was 
hyperplastic (n = 224, 72.7%). Characteristics of the 
resected polyps are described in Table 2. 
Table 3 shows the technical details of the endoscopy 
and polypectomy. Polypectomies were performed 
by a staff endoscopist in 268 cases (87%) and at 
university hospitals in 251 cases (81.5%). Hemorrhage 
prophylaxis was performed in 219 (71.1%) patients; 
the most common technique was injection of adrenaline 
alone or in combination with clips, endoloops and APC.
All the patients were successfully contacted. A 
total of 41 patients (13.3%) presented 45 unexpected 
events: 30 bleeding, 10 abdominal pain, 2 respiratory 
desaturation, 1 spontaneous bacterial peritonitis, 1 
esophageal laceration and 1 pneumothorax. However, 
following the ASGE lexicon, only 9 patients presented 
9 (2.9%; 95%CI: 1-4.8) events that were considered 
AEs, and 6 of them were bleeding (5 in stomach and 
1 in duodenum; 1.9%; 95%CI: 0.4-3.5). Severity and 
timing of these AEs are described in Table 4.
Bleeding was the most common unplanned event 
that occurred during the procedure (n = 30, 9.7%; 
95%CI: 6.4-13.1). The majority of episodes could 
be managed without any change in the outcome of 
the endoscopy and, consequently, were considered 
incidents (24 out of 30, 80%). In 13 out of 24 incidents 
(54.1%) and in 5 out of 6 AE (83.3%), different types 
of endoscopic treatment were performed: injection 
alone in 3, clips alone in 3, injection plus clips in 10 
and combination of injection, clips and APC in 2. In all 
the cases, bleeding was adequately controlled. Figure 2 
shows the relationship between the use of prophylactic 
measures, the presence and severity of bleeding and 
the use of endoscopic treatment. 
There were no statistically significant differences 
in terms of age, gender, polyp histology and location 
in stomach or duodenum, technical details of poly-
pectomy, hospital characteristics and use of prophy-
lactic measures between patients who developed 
hemorrhagic episodes and those who did not. Only 
polyp size and endoscopist expertise were statistically 
significant in the univariate but not in the multivariate 
analysis (Table 5). 
DISCUSSION
Bleeding is the most common adverse event of snare 
polypectomy in the upper gastrointestinal tract. In our 
study we found a 2.6% AEs rate (1.9% considering 
only bleeding) after resection of gastric and duodenal 
polyps which is lower than data reported in other 
series. To the best of our knowledge, this study is 
the first multicenter and prospective evaluation of 
AEs after gastroduodenal snare polypectomy using 
the lexicon recommended by the ASGE. Our results 
confirm the safety of gastric polypectomy when 
applying preventive measures and emphasize the need 
of using standardized systems to report AEs.
For years, polypectomy in the upper gastrointestinal 
Table 1  Characteristics of patients n  (%)
Characteristics Value
Age (yr), mean ± SD (range) 69.1 ± 11.8 (22-92)
Gender: M/F 111/197 (36/64)
Smoker 21 (6.8)
Alcohol 35 (11.4)
Cirrhosis 20 (6.5)
Anticoagulation 36 (11.7)
Indication
   Iron-deficiency anemia 103 (33.4)
   Polyp follow-up 68 (22.1)
   Dyspepsia/ GERD 51 (16.6)
   Upper hemorrhage 33 (10.7)
   Pernicious anemia 7 (2.3)
   Dysphagia 6 (1.9)
   FAP 4 (1.3)
   Others 36 (11.7)
ASA
   Ⅰ 34 (10.4)
   Ⅱ 202 (62)
   Ⅲ 88 (27)
   Ⅳ 2 (0.6)
GERD: Gastroesophageal reflux disease; FAP: Familial adenomatous 
polyposis; ASA: American Society of Anesthesiologist.
Table 2  Characteristics of polyps (the biggest in case of 
multiple polyps) n  (%)
Characteristics Value
Paris classification of polyps
   0- Is 152 (49.4)
   0-Ip 156 (50.6)
Size (mm), mean ± SD (range) 15 ± 8.9 mm (5-60)
Size
   5 mm 17 (5.5)
   6-10 mm 109 (35.4)
   11-20 mm 132 (42.9)
   > 20 mm 47 (15.3)
Location
   Fundus 50 (16.2)
   Body 112 (36.4)
   Incisura 5 (1.6)
   Antrum 119 (38.6)
   Pylorus 8 (2.6)
   Duodenum 14 (4.5)
Physician expertise
   Staff 268 (87)
   Fellow 40 (13)
Polyp histology
   Hyperplastic 224 (72.7)
   Adenoma 29 (9.4)
   Fundic glands hyperplasia 25 (8.1)
   Adenocarcinoma 8 (2.6)
   Inflammatory fibroid 7 (2.3)
   Neuroendocrine tumor 5 (1.6)
   Others1 7 (2.3)
   No retrieved 2 (0.6)
13 Brunner's gland hamartoma, 1 gastric inflammatory pseudopolyp, 1 
spindle cell lipoma, 1gastric heterotopia polyp, 1 cystic gastritis.
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tract was considered less secure than that of colonic 
polyps. Two prospective studies with a lower number 
of patients evaluated the safety of gastric polypectomy. 
Muehldorfer et al[14] studied the use of biopsy for 
the histological diagnosis of gastric polyps and the 
assessment of AEs was a secondary aim and the 
reported an incidence of hemorrhagic events was 7.2%. 
However, the definition of bleeding was broad including 
all the cases in which a therapeutic intervention was 
required regardless of the need of hospitalization or 
transfusion. Following the ASGE lexicon definition of 
AEs, the rate of AEs in this study would have been of 
three (1.3%): two bleeding episodes that required 
a blood transfusion and one perforation. The other 
prospective study is a Taiwanese comparative study 
that assessed the efficacy of submucosal epinephrine 
injection before polypectomy of 151 sessile polyps (87 
colonic and 64 upper GI) in the prevention of bleeding 
and perforation[18]. This study showed a total of nine 
(5.96%) episodes of post-polypectomy hemorrhage, 
eight of them were immediate, and two perforations, 
with a total of 7.3% complications. However, most of 
the hemorrhagic episodes occurred in foregut polyps 
(10.9% vs 2.3%), were immediate and were controlled 
with additional endoscopic treatment. Only two 
patients required blood transfusion, cutting down the 
number of hemorrhagic AEs in foregut polypectomies 
to 3.1%. 
Bardan et al[26] performed a retrospective study 
(102 patients with gastric polyps) in which the primary 
outcome was the occurrence of immediate or delayed 
bleeding episodes. Although they reported seven 
episodes of bleeding (6.9%), six were detected 
immediately after polypectomy and were adequately 
treated by injection. Only one episode was considered 
severe because it required a blood transfusion 6 
days after the polypectomy and fulfilled the definition 
of AEs by the ASGE lexicon, decreasing the rate of 
hemorrhagic AEs to 0.98%. The retrospective design 
of this study limits the conclusions and it could be 
argued that complication rate might be higher.
Kratzsch et al[27] in the largest retrospective analysis 
(1416 foregut polyps) also found a low complication 
rate (3.1%) that is close to our findings. However, 
there is a lack of relevant information concerning the 
definition of AEs and use of prophylactic measures, 
and the retrospective design of this study limits the 
conclusions since it may underestimate complications.
Information regarding the risks of duodenal 
resection is even scarcer. To date, the results of the 
two largest retrospective series treated with snare 
polypectomy showed a rate of hemorrhagic AEs of 
7.8%-11%[28,29] which is much higher than ours. 
Although duodenal polypectomy is usually technically 
more challenging than gastric polypectomy, location 
in the duodenum is not significantly associated with 
more hemorrhagic episodes, as showed in our study. 
We did not include flat polyps because these should 
be removed with mucosectomy which is technically 
challenging, more difficult than standard polypectomy, 
and associated with more AE’s.
Polyp size has proved to be the main risk factor 
for significant unexpected events in colonic polype-
ctomies. In fact, size is one factor that determines the 
complexity of polypectomy and as the complexity of 
polypectomy increases, a higher risk of complications 
is reported[30,31]. The overall perforation and bleeding 
rates in these series were very low (0.05% and 
0.65%, respectively). However, when the analysis was 
limited to bleeding requiring transfusion, unplanned 
hospital admission, interventional radiology or endo-
scopy, or surgery, the rate dropped to 0.13%. Again, 
Table 3  Endoscopy and polypectomy technical details
Characteristics n  (%)
Sedation 302 (98.1)
University Hospital 251 (81.5)
Endoscopist Staff 268 (87)
Number of polyps resected
   1 205 (66.6)
   2 55 (17.9)
   3 20 (6.5)
   4 8 (2.6)
   5 7 (2.3)
   > 5 13 (4.2)
Cautery settings
   Endocut 236 (76.6)
Hemorrhage prophylaxis 219 (71.1)
   One technique 149 (68)
   Two or more 70 (32)
Prophylactic technique
   Injection alone 119 (54.3)
   Clips 16 (7.3)
   Clips + injection 60 (27.4)
   Endoloop 9 (4.1)
   Endoloop + injection 5 (2.3)
   APC 5 (2.3)
   APC + injection 2 (0.9)
   APC+ clips + injection 3 (1.4)
APC: Argon plasma coagulation.
326 patients with gastroduodenal 
polypectomy
Polyp < 5 mm, n  = 1
Platelets < 50.000, n  = 1
Cold snare polypectomy, n  = 9
Ⅱb or Ⅱc polyp, n  = 7
308 patients 
included
294 with 
gastric polyos
14 with 
duodenal polyps
Figure 1  Study flow chart.
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these results emphasize the importance of using 
standardized systems for reporting AEs. Because 
hemorrhage prophylaxis was allowed in polyps larger 
than 20 mm which have a high likelihood of bleeding, 
this fact could explain that size was not associated with 
a higher rate of hemorrhagic AEs in our series. 
Although the rate of AEs in our study is low, the 
number of bleeding episodes is not negligible and many 
of them received prophylaxis (10.5%) or were treated 
endoscopically (60%) with injection, APC, hemostatic 
clips or a combination of methods which increases 
health care costs. Interestingly, the combination of two 
or more techniques did not improve the prophylactic 
effect of using one technique alone against bleeding. 
However, one could expect a higher number and more 
severe bleeding episodes if we had not systematically 
applied prophylactic measures, with an estimated high 
economical impact as well.  
This study has several strengths. First, it is a 
multicenter study performed in many hospitals (tertiary 
and community) with a different volume of explorations 
that increase the generalizability of the results. 
Second, preventive measures for post polypectomy 
bleeding were applied systematically. Third, all patients 
were systematically evaluated and reached three times 
(at 48 h, 7 and 30 d after the procedure), avoiding 
drop-outs that could bias the results. Fourth, we only 
included protruded polyps in order to avoid the use 
of other endoscopic resection techniques such as 
mucosectomy or endoscopic submucosal dissection 
which are more technically demanding and have a 
higher risk of complications. And finally, we used a 
standardized lexicon for endoscopic AEs.
One limitation of the study is that multiple polyps 
in the same patient were not considered separately 
and it is not possible to attribute the bleeding episode 
to the one that received prophylaxis or not. However, 
prophylactic measures were applied to the polyps 
with more risk of bleeding and the number of polyps 
was considered a variable in the analysis. The second 
limitation is that the number of AEs found is lower 
than the estimated figure used for the sample size 
calculation, which underpowers the results of the 
study. Unfortunately, this low rate prevented us from 
Table 4  Type and severity of adverse events according to ASGE lexicon
Unexpected events Time of presentation Severity 
(intraprocedural 
hemorrhage)
Admission or 
prolongation of 
hospitalization
Repeat 
endoscopy
AEs
ASGE lexicon
Type n  = 45 n  = 9 Severity
Hemorrhage 30 Intraprocedural, n = 26 Grade 1, n =11 Yes, n = 2 No 2 Mild
Grade 3, n =14
Grade 4, n =1
3 d, n = 1 No Yes 1 Moderate
7 d, n = 2 Yes Yes 2 Moderate (1)
Severe (1)
30 d, n = 1 Yes Yes 1 Moderate
Abdominal pain 10 24 h No No
Respiratory desaturation   2 Intraprocedural No No
Pneumothorax   1 Intraprocedural Yes No 1 Moderate
SBP   1 7 d Yes No 1 Severe
Esophageal laceration   1 Intraprocedural Yes No 1 Mild
SBP: Spontaneous bacterial peritonitis.
Hemorrhage prophylaxis Bleeding episodes AE/incident Hemorrhage treatment
No
n  = 89
Yes
n  = 7 (7.9%)
AE, n  = 2
Incident, n  = 5
Yes, n  = 2
57.1%
60.9%
Yes, n  = 2
Yes, n  = 3
Yes, n  = 11
Yes
n  = 219
Yes
n = 23 (10.5%)
AE, n  = 4
Incident, n  = 19
AE, 21.9%
Figure 2  Relationship between the use of prophylactic measures, the presence and severity of bleeding episodes and the use of endoscopic treatment.
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studying risk factors for polypectomy-related AEs. 
Finally, we used definitions of hemorrhage and criteria 
for prophylaxis that apply to colonic polyps because we 
did not find any specific definition for gastric polyps. 
However, we assume that the mechanism of post-
polypectomy hemorrhage must be similar regardless 
the localization of the polyp.
In conclusion, gastroduodenal polypectomy using 
prophylactic measures has a rate of AEs small enough 
to consider this procedure a safe and effective method 
for polyp resection independently of the polyp size and 
location. 
ARTICLE HIGHLIGHTS
Research background
Gastric and duodenal polypectomy is commonly performed. Although there is a 
theoretical increased risk of bleeding, there is scarce information regarding the 
potential adverse events (AEs) of polypectomy in this setting. The aim of this 
study was to evaluate the rate of AEs during consecutive gastric and duodenal 
polypectomies in several Spanish centers. 
Research motivation
The safety of polypectomy in the upper GI tract is controversial because the 
reported rate in retrospective studies is higher than in colonic polypectomy but 
results come mainly from retrospective studies and they do not use the same 
standardized nomenclature and definitions for adverse events.
Research objectives 
The aims of this study were to determine in a prospective study the rate of 
adverse events of gastroduodenal snare polypectomy for non-flat polyps; to 
evaluate the adverse events (early and late) that occur after a gastric and/or 
duodenal polypectomy as well as the predictive fractures for its development; 
to evaluate the different endoscopic techniques used in the prophylaxis of post-
polypectomy hemorrhage.
Research methods
The research methods: (1) Multicenter, longitudinal and prospective study of 
all patients undergoing polypectomy of gastric or duodenal polyps ≥ 5 mm 
using an electrocautery polypectomy snare; (2) Patients with PT < 50% and 
Table 5  Univariate analysis of bleeding risk factors n  (%)
Bleeding, n  = 30 No bleeding, n  = 278 P value
Age (yr), mean ± SD 69.5 ± 10 69.1 ± 12 0.137
Gender 0.634
   Male 12 (40) 99 (35.6)
   Female 18 (60) 179 (64.4)
Anticoagulation1 0.217
   Yes 14 (46.7) 98 (35.2)
   No 16 (53.3) 180 (64.7)
ASA 0.515
   I, II 20 (66.7) 201 (72.3)
   III, IV 10 (33.3) 77 (27.7)
Paris classification of polyps1
   0-Ip 17 (56.7) 135 (48.6) 0.399
   0-Is 13 (43.3) 143 (51.4)
Polyp size1 < 0.036
   ≤ 10 mm 7 (23) 120 (43.2)
   > 10 mm 23 (77) 158 (56.8)
Location 0.557
   Stomach 28 (93.3) 266 (95.7)
   Duodenum 2 (6.7) 12 (4.3)
Polyp histology1 0.092
   Hyperplastic 18 (60) 206 (74.4)
   Others 12 (40) 72 (25.6)
Polyp with dysplasia 0.053
   Yes 8 (26.7) 36 (13.4)
   No 22 (73.3) 232 (86.6)
Physician expertise1 < 0.026
   Staff 30 (100) 238 (85.6)
   Fellow 0 (0) 40 (14.4)
University hospital 0.207
    Yes 27 (90) 224 (80.6)
    No 3 (10) 54 (19.4)
Number of polyps resected 0.989
   One 20 (66.7) 185 (66.5)
   More than one 10 (33.3) 93 (33.4)
Use of endocut1 0.068
   Yes 27 (90) 209 (75.2)
   No 3 (10) 69 (24.8)
Hemorrhage prophylaxis1 0.479
   Yes 23 (76.7) 196 (70.5)
   No 7 (23.3) 82 (29.5)
1Clinically relevant variables that have been included in the multivariate analysis. 
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platelets < 50000 or clopidogrel in the 7 d prior to endoscopy were excluded; 
(3) Prophylactic measures of hemorrhage were allowed in certain predefined 
cases; (4) Intraprocedural hemorrhage was defined as bleeding that lasts more 
than 30 seconds and severity was graded from 1 to 4; (5) Late hemorrhage was 
defined as melena or hematochezia since discharge from endoscopy unit and 
up to 30 d. (6) Patients were followed during 30 d with serial phone calls; and (7) 
Predictive factors of complications were analyzed  
Research results
308 patients were included and a single polypectomy was performed in 205. 
Hemorrhage prophylaxis was performed in 219 (71.1%) patients. Nine patients 
presented AEs (2.9%), and 6 of them were bleeding (n = 6, 1.9%) (In 5 out 
of 6 AEs, different types of endoscopic treatment were performed). Other 24 
hemorrhagic episodes could be managed without any change in the outcome of 
the endoscopy and, consequently, were considered incidents. We did not find 
any independent risk factor of bleeding.
Research conclusions
The rate of adverse events of gastroduodenal snare polypectomy for non-flat 
polyp is low. However, the number of bleeding episodes is not negligible and 
many of them receive prophylaxis or are treated endoscopically with injection, 
APC, hemostatic clips or a combination of methods which increases health 
care costs. Prophylactic measures do not reduce the risk of hemorrhage. To 
our knowledge, this is the first study using the ASGE lexicon for reporting 
adverse events of gastro-duodenal polypectomy and shows an acceptable low 
rate, confirming the safety of this procedure. Because AEs of gastroduodenal 
polypectomies are low, there is no need of using more than one prophylactic 
endoscopic technique (clips, sclerosis, APC…) with the consequent reduction 
of costs.
Research perspectives
Gastroduodenal polypectomy using prophylactic measures has a rate of AEs 
small enough to consider this procedure a safe and effective method for polyp 
resection independently of the polyp size and location. The future research 
direction is to compare the use of prophylaxis or not before polypectomy in 
gastric polyps and the best method would be a prospective, comparative and 
randomized study.
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